Brind.
  1. NJBS donation centers are located in Scotch Plains, NJ, and operate as part of the larger NYBC network.
  2. NYBC serves the tri-state area, and updates to FDA guidance affect eligibility for donations.

New York Blood Center Appoints CEO and Secures FDA Approval for HemaCord

1 report, 1 independent Updated Mon 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

The Board of Trustees of New York Blood Center Enterprises appointed Meghan Delaney as President and Chief Executive Officer. She is set to assume the role on January 4, 2027. The organization also secured FDA approval for HemaCord, which is noted as the first FDA-licensed hematopoietic progenitor cell therapy product.

From prnewswire.com

Why it matters

Some supportBrind's analysis of the reports

The FDA approval of HemaCord expands the capabilities of the New York Blood Center as a life sciences enterprise. The appointment of Meghan Delaney as CEO signals a leadership transition for the organization.

New York Blood Center serves the tri-state area, and updates to FDA guidance affect eligibility for donations.

From prnewswire.com

Who's involved

  • New York Blood CenterOrganization that appointed the new CEO and received FDA approval for HemaCord
  • Meghan DelaneyAppointed President and Chief Executive Officer of the New York Blood Center
  • FDARegulatory agency that granted approval for the HemaCord product

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • New York Blood Center might see increased revenue and market standing due to the FDA approval of HemaCord.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped